Insight Molecular Diagnostics Inc. — Director's Dealing 2022

Apr 18, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2022-04-14

Reporting Person: PURA VIDA INVESTMENTS, LLC (10% Owner)
Reporting Person: Kamen Efrem (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-04-14	Common Stock	P	1665898	$1.3325	Acquired	7350447	Indirect
2022-04-14	Common Stock	P	30790	$1.2270	Acquired	7381237	Indirect
2022-04-14	Common Stock	P	92370	$1.2600	Acquired	7473607	Indirect
2022-04-14	Common Stock	P	1916419	$1.3325	Acquired	8455823	Indirect
2022-04-14	Common Stock	P	19210	$1.2270	Acquired	8475033	Indirect
2022-04-14	Common Stock	P	57630	$1.2600	Acquired	8532663	Indirect
2022-04-14	Common Stock	P	767952	$1.3325	Acquired	767952	Indirect
2022-04-14	Common Stock	P	1381438	$1.3325	Acquired	1381438	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-04-14	Warrant to purchase common stock	$1.53	P	832949	Acquired	2027-04-19	Common Stock (832949)	Indirect
2022-04-14	Warrant to purchase common stock	$1.53	P	383976	Acquired	2027-04-19	Common Stock (383976)	Indirect
2022-04-14	Warrant to purchase common stock	$1.53	P	690719	Acquired	2027-04-19	Common Stock (690719)	Indirect
2022-04-14	Warrant to purchase common stock	$1.53	P	958209	Acquired	2027-04-19	Common Stock (958209)	Indirect

Footnotes

F1: Each share of common stock was purchased together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325.

F2: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI.

F3: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any.

F4: The Warrants are subject to an ownership blocker provision that prevents the holder from exercising the Warrants if it would beneficially hold more than 19.99% of the common stock following such exercise.